This clinical trial is focused on studying a condition known as Postpartum Hemorrhage, which is excessive bleeding following childbirth. The study is specifically looking at women who have a condition called placenta previa, where the placenta is positioned low in the uterus and can cause complications during delivery. The trial is testing the effectiveness of a medication called Tranexamic Acid, also known by the code name LB1148, in reducing blood loss after a cesarean delivery. Tranexamic Acid is a chemical substance that helps prevent excessive bleeding by aiding blood clotting. The study will compare the effects of this medication to a placebo, which is a substance with no active therapeutic effect.

The purpose of the study is to determine if administering a low dose of Tranexamic Acid shortly after the baby is delivered can reduce the need for a blood transfusion before the mother is discharged from the hospital. Participants in the study will receive either Tranexamic Acid or a placebo through an injection shortly after their cesarean delivery. The study will monitor the amount of blood loss and whether a blood transfusion is needed, as well as any side effects that may occur. The trial will also look at other factors such as the mother’s recovery and overall health after delivery.

Throughout the study, participants will be observed for any potential side effects of Tranexamic Acid, such as nausea or dizziness, and for any serious complications like blood clots. The study will also assess the mother’s satisfaction with her delivery experience and her psychological well-being after childbirth. The trial aims to provide valuable information on whether Tranexamic Acid can be a safe and effective way to manage blood loss in women with placenta previa undergoing cesarean delivery.